Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.Recombinant Antibody
Secure your research with recombinant antibodies.
Abcepta’s premium range of 1000+ recombinant and biosimilar antibodies deliver batch-to-batch consistency, confirmed specificity, ease of scalability, and assurance of long-term supply. What recombinant antibody manufacturing production means for you is less time confirming the antibody reproducibly works in your system, and more time executing experiments and collecting data to advance your research.
View Abcepta Recombinant Antibodies
Recombinant Antibodies: The Antibody Technology That Solves Common Antibody Problems
Polyclonal and monoclonal antibodies have been the standard immunodetection reagent in different biomedical applications for more than forty years. Recently, shortcomings in both monoclonal and polyclonal antibodies are leading researchers to turn to antibodies manufactured by recombinant technologies.
REPRODUCIBILITY
A series of publications have illuminated the challenges of reproducible results using traditional commercial research-grade antibodies.
Nature 521, 274–276 (2015)
Nature 483, 531–533 (2012).
Clin. Chem. Lab. Med. 52, 765–766 (2014).
Arch. Pharmacol. 379, 385–388 (2009).
Nature Struct. Mol. Biol. 18, 91–93 (2011).
Mol. Cell. Proteom. 7, 2019–2027 (2008).
BioTechniques 48, 197–209 (2010).
Nature 518, 27–29 (2015).
The reproducibility issues in the data emanate from a host of parameters including batch-to-batch variation and non-specific antibody binding. Polyclonal Abs originate from animal serum and each batch is prepared from a different animal or a different immunization. Monoclonal Abs, originating from a single B-cell clone have since been shown to express additional functional variable regions, leading to non-specific binding, decreased binding signal, and a decreased signal-to-noise ratio.
Recombinant antibodies have been developed to deliver true monospecific highly-sensitive immunodetection reagents to life science researchers worldwide.
Cat# APR10143. Anti-CLDN6 Reference Antibody (IMAB027) on SDS-PAGE under reducing (R) condition.
The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%
What are Recombinant Antibodies?
Recombinant antibodies are a type of monoclonal antibodies that are generated in vitro from a synthetic gene without immunizing any animals or cultivating any hybridomas.
ADVANTAGES
Abcepta’s recombinantly manufactured antibodies help you achieve:
- Unrivaled batch-to-batch performance consistency
- Confirmed specificity that will not drift over time
- Scalability that ensures reliable, long-term supply of sequence-identical product
- Antibody production without the need for animals
Cat# APR10154. Immobilized human GPC3, His tag at 2 µg/mL can bind
Anti-GPC3 / Glypican-3 Reference Antibody (codrituzumab)，EC50=0.008741 µg/mL
Recombinant Abs have several advantages as compared to monoclonals. The first is the increased reproducibility of the technology. The sequence of recombinant Ab gene is known and cloned, making them more reliable and more reproducible than monoclonals. The second advantage of recombinant antibodies over monoclonal antibodies is the time required to generate them. Hybridomas need multiple months to produce effective Abs, while recombinant Abs technology decreases the production time to just a few weeks. Finally, the generation and manufacturing of recombinant antibodies are animal-free technologies. The production process of recombinant Abs does not involve any animals.
